Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 3 | 6 |
| 1.1 List of Tables | 5 | 2 |
| 1.2 List of Figures | 7 | 2 |
| 2 Global Anti-Hypertensives Market: Introduction | 9 | 2 |
| 2.1 GBI Research Report Guidance | 10 | 1 |
| 3 Global Anti-Hypertensives Market: Market Overview | 11 | 11 |
| 3.1 Introduction | 11 | 1 |
| 3.2 Revenue Forecasts for the Global Anti-Hypertensive Market | 12 | 1 |
| Sales Value | 12 | 1 |
| 3.2.2 Annual Cost of Therapy | 13 | 1 |
| 3.2.3 Treatment Usage Patterns | 14 | 2 |
| 3.2.4 Treatment-Seeking Population | 16 | 1 |
| 3.2.5 Diagnosed Population | 17 | 1 |
| 3.2.6 Prescription Population | 18 | 1 |
| 3.3 Anti-Hypertension Disorders Market Drivers | 19 | 1 |
| 3.3.1 Steady Increase in the Hypertension and Pulmonary Arterial Hypertension Prevalence Population | 19 | 1 |
| 3.3.2 Uptake of Fixed Dose Combination Therapies due to Better Efficacy in Hypertension and PAH | 19 | 1 |
| 3.3.3 Patent Expiries of Branded Drugs and Entry of Generics will Reduce the Annual Cost of Therapy with Anti-Hypertensives | 19 | 1 |
| 3.4 Anti-Hypertension Disorders Market Restraints | 20 | 1 |
| 3.4.1 Low Compliance in Hypertensive Patients | 20 | 1 |
| 3.4.2 Patent Expiries of Major Blockbusters Including Diovan, Avapro, Blopress/Atacand, Cozaar/Hyzaar and Tracleer, Pose a Threat to Market Revenues | 20 | 1 |
| 3.4.3 Low Treatment Seeking Behavior and Diagnosis in PAH | 20 | 1 |
| 3.5 Generics Share in the Global Anti-Hypertension Market | 21 | 1 |
| 4 Global Anti-Hypertensives Market: Therapeutic Landscape | 22 | 22 |
| 4.1 Hypertension | 22 | 1 |
| 4.1.1 Introduction | 22 | 1 |
| 4.1.2 Sales Value | 22 | 3 |
| 4.1.3 Annual Cost of Therapy | 25 | 1 |
| 4.1.4 Treatment Usage Patterns | 26 | 1 |
| 4.1.4.1 Treatment-Seeking Population | 27 | 1 |
| 4.1.4.2 Diagnosed Population | 28 | 1 |
| 4.1.4.3 Prescription Population | 29 | 1 |
| 4.1.5 Market Share by Geography | 30 | 3 |
| 4.2 Pulmonary Arterial Hypertension (PAH) Market | 33 | 1 |
| 4.2.1 Introduction | 33 | 2 |
| 4.2.2 Sales Value | 35 | 1 |
| 4.2.3 Annual Cost of Therapy | 36 | 1 |
| 4.2.4 Treatment Usage Patterns | 37 | 1 |
| 4.2.4.1 Treatment-Seeking Population | 38 | 1 |
| 4.2.4.2 Diagnosed Population | 39 | 1 |
| 4.2.4.3 Prescription Population | 40 | 1 |
| 4.2.5 Market Share by Geography | 41 | 3 |
| 5 Global Anti-Hypertensives Market: Geographical Landscape | 44 | 21 |
| 5.1 Geographical Break-up | 44 | 3 |
| 5.2 The US | 47 | 1 |
| 5.2.1 Sales Value | 47 | 1 |
| 5.2.2 Annual Cost of Therapy | 48 | 1 |
| 5.2.3 Treatment Usage Patterns | 49 | 1 |
| 5.2.4 Treatment-Seeking Population | 50 | 1 |
| 5.2.4.1 Diagnosed Population | 51 | 1 |
| 5.2.4.2 Prescription Population | 52 | 1 |
| 5.3 Top Five Countries in Europe | 53 | 1 |
| 5.3.1 Sales Value | 53 | 1 |
| 5.3.2 Annual Cost of Therapy | 54 | 1 |
| 5.3.3 Treatment Usage Patterns | 55 | 1 |
| 5.3.3.1 Treatment-Seeking Population | 56 | 1 |
| 5.3.3.2 Diagnosed Population | 57 | 1 |
| 5.3.3.3 Prescription Population | 58 | 1 |
| 5.4 Japan | 59 | 1 |
| 5.4.1 Sales Value | 59 | 1 |
| 5.4.2 Annual Cost of Therapy | 60 | 1 |
| 5.4.3 Treatment Usage Patterns | 61 | 1 |
| 5.4.3.1 Treatment-Seeking Population | 62 | 1 |
| 5.4.3.2 Diagnosed Population | 63 | 1 |
| 5.4.3.3 Prescription Population | 64 | 1 |
| 6 Global Anti-Hypertensives Market: Pipeline Analysis | 65 | 18 |
| 6.1 Introduction | 65 | 1 |
| 6.1.1 Research and Development Pipeline Hypertension | 66 | 6 |
| 6.1.2 Research and Development Pipeline Pulmonary Arterial Hypertension | 72 | 4 |
| 6.2 Profiles of Key Late-Stage Drugs in the Anti-Hypertension Market | 76 | 1 |
| 6.2.1 SPP635 | 76 | 1 |
| 6.2.1.1 Introduction | 76 | 1 |
| 6.2.1.2 Efficacy | 76 | 1 |
| 6.2.1.3 Safety | 76 | 1 |
| 6.2.1.4 Clinical Study Details | 76 | 1 |
| 6.2.2 Pioglitazone | 77 | 1 |
| 6.2.2.1 Introduction | 77 | 1 |
| 6.2.2.2 Efficacy | 77 | 1 |
| 6.2.2.3 Safety | 77 | 1 |
| 6.2.2.4 Clinical Study Details | 77 | 1 |
| 6.2.3 LCZ696 | 78 | 1 |
| 6.2.3.1 Introduction | 78 | 1 |
| 6.2.3.2 Efficacy | 78 | 1 |
| 6.2.3.3 Safety Profile | 78 | 1 |
| 6.2.3.4 Clinical Study Details | 78 | 1 |
| 6.2.4 QT1571 (imatinib) | 78 | 1 |
| 6.2.4.1 Introduction | 78 | 1 |
| 6.2.4.2 Efficacy | 78 | 1 |
| 6.2.4.3 Safety | 78 | 1 |
| 6.2.4.4 Clinical Study Details | 79 | 1 |
| 6.2.5 Selexipag (NS-304, ACT-293987) | 79 | 1 |
| 6.2.5.1 Introduction | 79 | 1 |
| 6.2.5.2 Efficacy | 79 | 1 |
| 6.2.5.3 Safety | 79 | 1 |
| 6.2.5.4 Clinical Study Details | 79 | 1 |
| 6.2.6 PS-433540 (DARA) | 80 | 1 |
| 6.2.6.1 Introduction | 80 | 1 |
| 6.2.6.2 Efficacy | 80 | 1 |
| 6.2.6.3 Safety | 80 | 1 |
| 6.2.6.4 Clinical Study Details | 80 | 1 |
| 6.2.7 Macitentan (ACT-064992, Actelion 1) | 80 | 1 |
| 6.2.7.1 Introduction | 80 | 1 |
| 6.2.7.2 Efficacy | 81 | 1 |
| 6.2.7.3 Safety | 81 | 1 |
| 6.2.7.4 Clinical Study Details | 81 | 1 |
| 6.2.8 Riociguat (BAY63-2521) | 81 | 1 |
| 6.2.8.1 6.2.8.1 Introduction | 81 | 1 |
| 6.2.8.2 Efficacy | 81 | 1 |
| 6.2.8.3 Safety | 81 | 1 |
| 6.2.8.4 Clinical Study Details | 81 | 2 |
| 7 Global Anti-Hypertensives Market: Competitive Landscape | 83 | 9 |
| Market Share Analysis: Hypertension Disorders | 83 | 1 |
| 7.2 Competitive Profiling | 84 | 1 |
| 7.2.1 Novartis | 84 | 1 |
| 7.2.1.1 Product Portfolio | 84 | 1 |
| 7.2.2 Merck | 85 | 1 |
| 7.2.2.1 Product Portfolio | 85 | 1 |
| 7.2.3 AstraZeneca | 86 | 1 |
| 7.2.3.1 Product Portfolio | 86 | 1 |
| 7.2.4 United Therapeutics | 87 | 1 |
| 7.2.4.1 Product Portfolio | 87 | 2 |
| 7.2.5 Actelion | 89 | 1 |
| 7.2.5.1 Product Portfolio | 89 | 1 |
| 7.2.6 Pfizer | 90 | 1 |
| 7.2.6.1 Product Portfolio | 90 | 2 |
| 8 Global Anti-Hypertensives Market: Strategic Consolidations | 92 | 7 |
| 8.1 Overview | 92 | 1 |
| 8.2 Deals by Type | 93 | 1 |
| 8.2.1 Eli Lilly Acquires ICOS in January 2007 | 93 | 1 |
| 8.2.2 Abbott Laboratories Acquires Solvay Pharmaceuticals in February 2010 | 93 | 1 |
| 8.2.3 Endo Pharmaceuticals to Acquire Qualitest Pharmaceuticals in 2010 | 94 | 1 |
| 8.2.4 Jubilant Organosys Acquires Trinity Laboratories and Trigen Laboratories in March 2007 | 94 | 1 |
| R&D Licensing Agreements | 94 | 1 |
| 8.3.1 Deals by Indication | 94 | 1 |
| 8.3.2 Deals by Phase | 95 | 1 |
| 8.3.3 Deals by Geography | 95 | 1 |
| 8.3.4 Phase II | 96 | 1 |
| 8.3.4.1 EG-PO42 | 96 | 1 |
| 8.3.4.2 NS304 | 96 | 1 |
| 8.3.4.3 Aviptadil | 96 | 1 |
| 8.3.5 Approved | 97 | 1 |
| 8.3.5.1 Diovan | 97 | 1 |
| 8.3.5.2 Olmotec | 97 | 1 |
| 8.3.5.3 Futuran | 97 | 1 |
| 8.3.5.4 Letairis | 97 | 1 |
| 8.3.5.5 Remodulin | 98 | 1 |
| 9 Global Anti-Hypertensives Market: Appendix | 99 | 5 |
| 9.1 Market Definitions | 99 | 1 |
| 9.2 Abbreviations | 99 | 2 |
| 9.3 Research Methodology | 101 | 2 |
| 9.3.1 Coverage | 101 | 1 |
| 9.3.2 Secondary Research | 101 | 1 |
| 9.3.3 Primary Research | 101 | 1 |
| 9.3.4 Expert Panel Validation | 102 | 1 |
| 9.4 Contact Us | 102 | 1 |
| 9.5 Disclaimer | 102 | 1 |
| 9.6 Sources | 103 | 1 |